A
A
Home
Global websites
Local websites
Locations map

Press Releases

2024

August 28, 2024
argenx to Present at Upcoming Investor Conferences
July 25, 2024
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
July 18, 2024
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 16, 2024
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
June 25, 2024
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
June 21, 2024
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
June 17, 2024
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
June 4, 2024
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
May 9, 2024
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
argenx announces results of Annual General Meeting of Shareholders
May 7, 2024
argenx to Present at BofA Securities 2024 Health Care Conference
May 2, 2024
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024